drugset / Trial / NCT03348423

Evaluation of DEX-IN During Outpatient Procedures

NCT03348423

Phase 2 Completed 45 enrolled Baudax Bio
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the analgesic efficacy of DEX-IN compared with placebo and active control (fentanyl), in subjects undergoing painful outpatient and office based procedures.

Timeline

Start
2017-11-15
Primary completion
2018-01-18
Completion
2018-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 50 ug Intranasal
Comparator Fentanyl Other / unclassified 50 ug Intravenous

Indications

No indication recorded.